This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD.
Engineered (spray dried) powder formulations were associated with relatively high TLD (> 50% of nominal dose) compared to lactose blend and agglomerate based formulations, which had a lower TLD (7 40% of nominal dose), indicative of less efficient targeting of the lung.
The correlations between the deposition, retained B dose/profile, carrier dose/profile, sheet resistance (RS) as a function of the pulse voltage, nominal dose, and carrier gas dilution have been extensively investigated.
Albuterol delivery in NIV varied between 6.73 ± 0.44% to 37.01 ± 4.31% of the nominal dose.
A linear proportionality existed across the concentration range between nominal dose and both fine particle dose/fraction and emitted dose, with R2 > 0.999 in all cases.
Conventional opposed lateral WBRT radiation fields were applied to these patient-specific image sets and planned with the same nominal dose of 30 Gy in 10 fractions.
This study demonstrated better aerosol delivery to the lungs (between 10.5 and 15.1 % of the nominal dose) through an endotracheal tube as compared to previous scintigraphic studies (2.1 5.3 % of the nominal dose) [13, 14, 16].
Around 3%% of the nominal dose was retained on the nebulizer reservoir at the end of nebulization.
Results Irrespective of the nebulizer position, Inspi-Neb produced higher inhaled dose (p < 0.01; +6.3 to +16.8 % of the nominal dose), lower expiratory wasted dose (p < 0.05; −2.7 to −42.6 % of the nominal dose) and lower total lost dose (p < 0.05; −6.3 to 20.6 % of the nominal dose) than Conti-Neb.
As well, high dose antiinfectives with a nominal dose > 1 mg, become dissolution limited when the solubility <100 μg/mL (e.g., ciprofloxacin betaine, amphotericin B).
Results Lung deposition was only 3.3 ± 1.3 and 1.2 ± 0.8% of the nominal dose with the vibrating-mesh nebulizer and the jet nebulizer, respectively (p < 0.05).
